{"id":396201,"date":"2020-12-09T07:43:19","date_gmt":"2020-12-09T12:43:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=396201"},"modified":"2020-12-09T07:43:19","modified_gmt":"2020-12-09T12:43:19","slug":"ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/","title":{"rendered":"RA Capital Management Leads $45M Series A Financing for PepGen\u2019s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases"},"content":{"rendered":"

\nPepGen\u2019s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also participated in the Series A round
\n<\/h2>\n
\n

BOSTON and OXFORD, United Kingdom, Dec. 09, 2020 (GLOBE NEWSWIRE) — PepGen<\/strong>, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company\u2019s original seed investor. The University of Oxford and CureDuchenne Ventures, a leading patient advocacy group, also participated in the round.<\/p>\n

\n PepGen<\/a> will use the funding to advance into the clinic their next-generation cell-penetrating peptides conjugated to phosphorodiamidate morpholino oligomers (PPMOs) that are designed to correct genetic defects in diseases with high unmet medical need. PepGen\u2019s proprietary PPMO technology will dramatically enhance delivery of oligonucleotides to key tissues, while also improving safety compared with competing therapies.<\/p>\n

\u201cPepGen\u2019s cell-penetrating peptide (CPP) technology represents an important step change in that we have succeeded in optimizing cellular uptake whilst simultaneously engineering out the safety signals that historically impacted earlier attempts at this approach,\u201d said PepGen co-founder Matthew Wood, professor of neuroscience at the University of Oxford. \u201cI am delighted to see our progress validated by support from top-tier investors, and look forward to seeing translation into the clinic.\u201d<\/p>\n

One of PepGen\u2019s lead indications, DMD is a devastating genetic neuromuscular disorder affecting one in 3,500-5,000 male births around the world.<\/p>\n

\u201cPatients born with Duchenne muscular dystrophy lack dystrophin, a critical protein that confers structural integrity on muscle,\u201d said Caroline Godfrey, PhD, CEO and co-founder of PepGen. \u201cPepGen is developing unique, proprietary cell-penetrating peptides that we expect will improve upon the efficacy of existing exon-skipping approaches to restore dystrophin expression in DMD patients.\u201d<\/p>\n

A key benefit of PepGen\u2019s platform is its unique potential to reach all the tissues affected by DMD and other inherited neuromuscular and cardiovascular conditions. Notably, unlike other approaches, PepGen\u2019s drug candidates strongly distribute to cardiac tissue. Heart disease is a key cause of morbidity and mortality in these devastating conditions.<\/p>\n

\u201cA unique distinction of the PepGen peptides is that they can penetrate cardiac tissue, addressing a major and growing problem DMD patients face as they get older,\u201d said Ramin Farzaneh-Far, MD, venture partner at RA Capital Management, PepGen\u2019s executive chair, and a board-certified cardiologist. \u201cWith the recent approvals of treatments that generate small increases in dystrophin in skeletal muscle, patients may be ambulating and living longer, but this in turn is expected to shift the burden of morbidity and mortality towards an epidemic of heart disease, which is not adequately addressed by current DMD therapies.\u201d<\/p>\n

Said Debra Miller, CEO of CureDuchenne Ventures, \u201cPepGen, we believe, represents a potential breakthrough approach for which DMD patients and their caregivers have been hoping against hope. Virtually all Duchenne patients have cardiomyopathy, and cardiac failure is prevalent amongst this population, so therapies addressing this unmet need promise a major impact for the Duchenne community.\u201d<\/p>\n

In addition to DMD, PepGen has a pipeline of drugs targeting rare neuromuscular and neurologic diseases, with a particular focus on those with severe cardiac manifestations as well as primary cardiac conditions.<\/p>\n

\u201cWe consider ourselves lucky to be a part of this unique story. The ability of this technology to deliver life-saving drugs to all the organs and tissues affected by these devastating diseases offers real hope for total treatment of these conditions,\u201d said Joshua Resnick, MD, managing director at RA Capital Management and member of the PepGen board of directors.<\/p>\n

PepGen\u2019s cell-penetrating peptide technology for oligonucleotide delivery was developed over more than a decade of research in the UK, and arose from collaborations between the neuroscience laboratory of Professor Wood at the University of Oxford and the peptide chemistry laboratory of Dr. Mike Gait at the MRC Laboratory of Molecular Biology in Cambridge.<\/p>\n

With a seed investment of \u00a34.5 million from OSI, PepGen was spun out in 2018 to commercialize the cell-penetrating peptide platform. The company was additionally supported by a prestigious \u00a31.6 million grant from Innovate UK, the UK\u2019s innovation agency.<\/p>\n

\u201cDelivery is a challenge many innovative therapeutic platforms face; we\u2019re proud of the team\u2019s achievements to date as PepGen\u2019s CPP technology opens up a broad set of opportunities in gene therapy and gene modulation,\u201d said Uciane Scarlett, PhD, OSI\u2019s investment principal. Christopher Ashton, PhD, advisor to OSI, will continue to serve on PepGen\u2019s board of directors.<\/p>\n

PepGen\u2019s new corporate headquarters will be in Boston, and its research hub will continue in the UK.<\/p>\n

\n About RA Capital Management<\/strong>
\n
RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital Management to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, allowing management teams to drive value creation from inception through commercialization.<\/p>\n

At RA Capital\u2019s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides market intelligence, technical diligence, and other resources to both our internal Investment Team and our portfolio companies. The team\u2019s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, and public market dynamics.<\/p>\n

\n About <\/strong>
\n Oxford Sciences Innovation<\/strong>
\n
Oxford Sciences Innovation (OSI) is a leading science and technology business. OSI ensures Oxford\u2019s world-leading science moves out of the laboratory and onto the global stage. In partnership with the University of Oxford, OSI creates fundamental technology companies, built on science. We match scientists with experienced entrepreneurs and patient capital to turn idea to impact, discovery to company. OSI invests in Life Sciences, Deep Tech, Healthtech, AI and Software to create companies taking on challenges like diagnosis and treatment of disease and cancer, hyper resolution microscopy, renewable energy, drones, nuclear fusion and quantum computing. Founded in 2015, we\u2019ve raised over $800M of evergreen capital, building on Oxford\u2019s renowned research legacy, to create a leading science and technology ecosystem and home for entrepreneurs.<\/p>\n

OSI backs companies from their inception and invest for the long-term, helping them to build their businesses by finding senior management talent, entrepreneurs, expert advisors and global investors to realise their vision. OSI reinvests any returns back into the Oxford ecosystem and the next generation of scientists and technologies to create even more companies capable of tackling more of the world\u2019s most important problems.<\/p>\n

\n About <\/strong>
\n the University of Oxford<\/strong>
\n
Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the fifth year running, and at the heart of this success is our ground-breaking research and innovation. Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions. Through its research commercialization arm, Oxford University Innovation, Oxford is the leading university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 200 new companies since 1988. Over a third of these companies have been created in the past three years.<\/p>\n

\n About Duchenne Muscular Dystrophy<\/strong>
\n
Duchenne muscular dystrophy (DMD) is a rare, lethal, inherited neuromuscular disease that occurs in approximately one in every 3,500-5,000 male births globally. It is caused by a mutation in the gene that encodes instructions for dystrophin, a key structural protein. Symptoms of DMD usually appear in infants and toddlers. Affected children may experience developmental delays such as difficulty in walking, climbing stairs or standing from a sitting position. As DMD progresses, muscle weakness in the lower extremities spreads to the arms, neck and other areas. Most patients require full-time use of a wheelchair in their early teens, and then progressively lose the ability to independently perform activities of daily living. Eventually, patients have difficulty in breathing due to respiratory muscle dysfunction, which ultimately may require ventilatory support. Cardiac muscle dysfunction frequently leads to heart failure and death. The condition is universally fatal, and patients usually succumb to the disease in their twenties.<\/p>\n

Media Contact:
Michael-Jon Romano
Sommerfield Communications
+1 (212) 255-8386
Michael-Jon@Sommerfield.com<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PepGen\u2019s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also participated in the Series A round BOSTON and OXFORD, United Kingdom, Dec. 09, 2020 (GLOBE NEWSWIRE) — PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company\u2019s original seed investor. The University of Oxford and CureDuchenne Ventures, a leading patient advocacy group, also participated in the round. PepGen will use the funding to advance into the clinic their next-generation cell-penetrating peptides conjugated to phosphorodiamidate morpholino oligomers (PPMOs) that … <\/p>\n

Continue reading “RA Capital Management Leads $45M Series A Financing for PepGen\u2019s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-396201","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRA Capital Management Leads $45M Series A Financing for PepGen\u2019s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RA Capital Management Leads $45M Series A Financing for PepGen\u2019s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PepGen\u2019s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also participated in the Series A round BOSTON and OXFORD, United Kingdom, Dec. 09, 2020 (GLOBE NEWSWIRE) — PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company\u2019s original seed investor. The University of Oxford and CureDuchenne Ventures, a leading patient advocacy group, also participated in the round. PepGen will use the funding to advance into the clinic their next-generation cell-penetrating peptides conjugated to phosphorodiamidate morpholino oligomers (PPMOs) that … Continue reading "RA Capital Management Leads $45M Series A Financing for PepGen\u2019s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-09T12:43:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTQzMSMzODYyODMwIzUwMDA3NjI4NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"RA Capital Management Leads $45M Series A Financing for PepGen\u2019s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases\",\"datePublished\":\"2020-12-09T12:43:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\\\/\"},\"wordCount\":1436,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTQzMSMzODYyODMwIzUwMDA3NjI4NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\\\/\",\"name\":\"RA Capital Management Leads $45M Series A Financing for PepGen\u2019s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTQzMSMzODYyODMwIzUwMDA3NjI4NQ==\",\"datePublished\":\"2020-12-09T12:43:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTQzMSMzODYyODMwIzUwMDA3NjI4NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTQzMSMzODYyODMwIzUwMDA3NjI4NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RA Capital Management Leads $45M Series A Financing for PepGen\u2019s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RA Capital Management Leads $45M Series A Financing for PepGen\u2019s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/","og_locale":"en_US","og_type":"article","og_title":"RA Capital Management Leads $45M Series A Financing for PepGen\u2019s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases - Market Newsdesk","og_description":"PepGen\u2019s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also participated in the Series A round BOSTON and OXFORD, United Kingdom, Dec. 09, 2020 (GLOBE NEWSWIRE) — PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company\u2019s original seed investor. The University of Oxford and CureDuchenne Ventures, a leading patient advocacy group, also participated in the round. PepGen will use the funding to advance into the clinic their next-generation cell-penetrating peptides conjugated to phosphorodiamidate morpholino oligomers (PPMOs) that … Continue reading \"RA Capital Management Leads $45M Series A Financing for PepGen\u2019s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-09T12:43:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTQzMSMzODYyODMwIzUwMDA3NjI4NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"RA Capital Management Leads $45M Series A Financing for PepGen\u2019s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases","datePublished":"2020-12-09T12:43:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/"},"wordCount":1436,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTQzMSMzODYyODMwIzUwMDA3NjI4NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/","name":"RA Capital Management Leads $45M Series A Financing for PepGen\u2019s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTQzMSMzODYyODMwIzUwMDA3NjI4NQ==","datePublished":"2020-12-09T12:43:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTQzMSMzODYyODMwIzUwMDA3NjI4NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTQzMSMzODYyODMwIzUwMDA3NjI4NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ra-capital-management-leads-45m-series-a-financing-for-pepgens-next-generation-oligonucleotide-platform-targeting-duchenne-muscular-dystrophy-and-other-rare-neuromuscular-and-cardiac-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"RA Capital Management Leads $45M Series A Financing for PepGen\u2019s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=396201"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396201\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=396201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=396201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=396201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}